Hello and welcome to another edition of The Weekly Dose!

You started your GLP-1 with a plan — maybe even with a level of hope you hadn't felt in a long time. But somewhere along the way, something feels off. Progress has slowed. Or maybe it never started the way you expected. And the hardest part? You're doing everything you think you're supposed to be doing.

Here's the key thing to remember: GLP-1 medications are profoundly personal. A brand-new study out of Stanford Medicine just confirmed what many of us have suspected — roughly 10% of people carry genetic variants that cause a condition called "GLP-1 resistance," where their bodies simply don't respond to the medication the way most people do. That's a remarkable, real biological reason your results might look different from someone else's.

But genetics aside, there are also five very common, very fixable mistakes that quietly hold people back from their best results. This week, we're breaking all of them down — because you deserve a journey that's actually built around you.

💡 Let's dive in!

📌 Here's what's inside this issue:
✅ Announcement: The Weekly Dose Community is LIVE!
✅ Main Topic: 5 Common Mistakes That Cost You Personalized Progress on GLP-1s
✅ Research Recap: Why Ozempic Doesn't Work for Everyone — Scientists Just Found a Hidden Reason
✅ Question of the Week: What's one mistake you've caught yourself making?

💊 Not on a GLP-1 yet? Zealthy offers 100% online GLP-1 weight loss care — get started for just $39, with or without insurance. 200,000+ prescriptions written. → Check your eligibility here

Quick Reminder: The Weekly Dose Community is LIVE! If you've been waiting for a place to stay accountable, share progress, and connect with others on the GLP-1 journey — it's here.

Inside the Weekly Dose Skool Community, you'll find: 🏆 Weekly Wins — celebrate your progress and get inspired by others 📊 Accountability Challenges — small, sustainable goals to keep momentum 💬 Peer Support & Q&A — ask questions, get real feedback, share what's working 🎥 Expert Insights — resources and replays from trusted health pros

Whether you're on Mounjaro, Wegovy, Ozempic, Zepbound, or just starting out — this space was built for you.

👉 Join us here: https://www.skool.com/the-weekly-dose-8554/about

Let's keep showing up for ourselves — and for each other. 💪🚀

Nobody starts a GLP-1 journey planning to get in their own way. But these five mistakes show up again and again in our community — and most of the time, the people making them don't even realize it. That changes today.

Here's how it usually starts. You join a GLP-1 community, and within a week you see someone post that they've lost 25 pounds in 60 days. You've lost 8. And suddenly, 8 doesn't feel like enough.

That comparison isn't just emotionally draining — it's fundamentally misleading. Response to GLP-1 medications is shaped by a staggering number of individual factors: baseline insulin resistance, gut microbiome composition, thyroid function, sleep quality, stress hormone levels, and now, as we'll cover in this week's Research Recap, even your genetics. A brand-new study from Stanford Medicine found that roughly 1 in 10 people carry genetic variants that cause reduced GLP-1 response. The medication works — it just works differently for different bodies.

What actually matters is your own trend. Are you losing consistently, even slowly? Has your hunger dropped? Are your energy and blood sugar readings improving? Those are signs the medication is doing its job, even if the scale isn't keeping up with someone else's. Sound familiar?

Your action step: Track only your personal metrics — weight trend, energy, hunger ratings, lab numbers, clothing fit. Stop measuring your mile time against someone else's race.

GLP-1s suppress your appetite. That's the whole point. But here's the sneaky problem: when you're barely hungry, it becomes very easy to under-eat — especially protein. And when you lose weight without adequate protein, a significant portion of that loss can come from lean muscle mass, not fat.

This matters more than most people realize. Muscle is metabolically active tissue — it burns calories even at rest. Losing it slows your long-term metabolism and makes weight maintenance significantly harder down the road. A 2024 systematic review and network meta-analysis in Obesity Reviews found that lean mass loss is a real and meaningful concern for people on GLP-1 receptor agonists, making protein intake one of the most crucially important lifestyle variables on these medications.

The research-backed target is roughly 0.7–1 gram of protein per pound of body weight per day. That can feel impossible when your appetite is at rock bottom. The trick is making protein the only non-negotiable — even on your lowest-appetite days. A morning protein shake before the appetite suppression kicks in fully. A handful of cottage cheese before lunch. Two hard-boiled eggs you barely have to think about. (This is where it gets real.) Even 30 seconds of planning can be the difference between preserving and losing your muscle.

One member of our community shared that she was losing weight but feeling exhausted and foggy, losing hair, and noticing her arms looked "thin in a bad way." When she started tracking only her protein — nothing else — she realized she was averaging 35 grams a day. She bumped it to 90 grams using a morning protein shake and prioritizing chicken or fish at dinner. Within three weeks, her energy returned and the hair shedding slowed noticeably.

💪 If you need a clean, easy way to hit your protein goals without forcing food, Thorne's Whey Protein Isolate delivers 21g of protein per serving with minimal calories — and it's NSF Certified for quality. → Check out Thorne Protein here

This is one of the most common — and most costly — mistakes in the GLP-1 space. So many of us were raised to not be "difficult" patients. We don't want to seem like we're complaining. We don't want to ask for a dose adjustment too soon. So we quietly tolerate side effects, plateaus, and suboptimal results for months without saying a word to our prescriber.

Here's the thing: your provider genuinely cannot personalize your treatment if they don't know what's really going on for you. Is your appetite suppression wearing off two days before your next injection? Are you dealing with fatigue that's affecting your workouts? Is nausea hitting harder than you've let on? These are all critical data points that could lead to a better dose, a different injection day, or a medication switch that transforms your results.

The most impactful thing you can do is become the most communicative patient in your provider's practice. Write down how you feel each week. Track patterns. Then show up to appointments with real information — not a shrug and "it's going okay." You deserve a treatment plan that's actually designed for your unique biology, and your provider needs your honest feedback to build it.

The scale is one of the worst tools for measuring GLP-1 success — especially in the short term. Water retention, muscle gain, hormonal shifts, inflammation from a new exercise routine — any of these can make your weight go up or stay flat even when your body is profoundly changing.

Let's break this down. People on GLP-1s regularly experience enormous wins that the scale will never show: an HbA1c that drops from 7.8 to 5.9, a blood pressure medication that gets eliminated, going down two pant sizes while the scale barely budges, sleeping through the night for the first time in years. These are genuinely impactful health transformations. But if you're only watching a number, you'll miss them entirely.

Here's what I'd recommend: start a simple weekly NSV log. Just a note on your phone where you write down anything that felt better, fit better, moved better, or looked different this week. A flight of stairs that didn't leave you winded. A jeans button that finally closed. A lunch where you left food on the plate without thinking about it. Over time, this becomes the most motivating document you own.

GLP-1 medications are designed to be titrated — meaning you're expected to move up in dose over time to find your therapeutic level. But a lot of people get comfortable at a lower dose, or they're nervous about side effects at higher levels, and they stay put long after that dose has stopped doing its job.

Here's how to recognize it: your appetite is noticeably stronger than it was at a lower dose, you're eating larger portions than a few weeks ago, your hunger is returning noticeably before your injection day, or your weight has been flat for 4–6 weeks without an obvious lifestyle reason. These aren't signs of failure. They're essentially your body telling you it's ready for the next step.

This is another place where communication with your provider is crucial. Don't assume staying comfortable is the right call — ask the question. "Is it time to move up?" Your provider can walk you through the risk-benefit picture and create a plan that keeps you progressing safely. Notably, some research suggests that longer-acting formulations may even help overcome some forms of GLP-1 resistance — another reason the conversation with your provider is worth having.

Five mistakes, five fixes. None of them require perfection — they just require a little more self-awareness and a willingness to treat your GLP-1 journey as the personalized, ongoing experiment it truly is. You're not doing this wrong. You're figuring it out. And that's exactly what this community is here to help with.

Got a mistake you'd add to this list? Hit reply — I read every one.

🟢 Zealthy makes GLP-1 access simple — 100% online, prior auth support included, and plans starting at just $39. Most patients lose an average of 20% of their body weight in a year. → See if you qualify

💳 No insurance? No problem. Zealthy works with or without it. → Browse options

No insurance? Sesame Care offers transparent flat-rate GLP-1 visits — no hidden fees. → Browse pricing

Have you ever wondered why two people on the same GLP-1 medication, at the same dose, can have completely different results? It turns out there may be a hidden biological reason — and a team at Stanford Medicine just published the most detailed investigation of it yet.

✔️ About 10% of the population carries specific variants in a gene called PAM (peptidyl-glycine alpha-amidating monooxygenase) — an enzyme that plays a key role in activating the GLP-1 hormone. People with these variants appear to have higher circulating GLP-1 levels than normal, but their bodies don't respond to the hormone effectively. Researchers are calling this "GLP-1 resistance."

✔️ In a combined analysis of three clinical trials involving 1,119 participants, people with PAM variants were significantly less likely to reach their target blood sugar levels after six months of GLP-1 treatment. About 25% of participants without the variants met HbA1c targets, compared with only 11.5% of those carrying the primary PAM variant (p.S539W).

✔️ The resistance appears to be specific to GLP-1 medications — people with PAM variants responded normally to other common diabetes drugs like metformin and sulfonylureas. This suggests the issue is a downstream problem in the GLP-1 pathway, not a broad medication sensitivity issue.

If you've been doing everything right and still feeling like your results don't match your effort, this research is a meaningful piece of the puzzle. Biology — and specifically your genetics — plays a profound role in how your body responds to GLP-1s. This isn't about willpower or effort. It's about understanding your unique starting point. The researchers also noted that longer-acting GLP-1 formulations may help overcome some of this resistance — which is another reason open communication with your provider is so empowering.

Want to read the full study? Read it here: Umapathysivam et al., Genome Medicine, 2026

GLP-1 response varies significantly across individuals due to a combination of genetic, metabolic, and lifestyle factors. A 2026 Stanford Medicine study published in Genome Medicine (Umapathysivam et al.) identified a specific genetic mechanism — variants in the PAM gene — that causes "GLP-1 resistance" in approximately 10% of the population. These individuals produce higher-than-normal GLP-1 hormone levels but don't respond to it effectively. Other contributing factors include baseline insulin resistance, gut microbiome composition, and medication adherence.

The International Society of Sports Nutrition recommends 1.4–2.0 grams of protein per kilogram of body weight per day for adults aiming to preserve lean mass (Jäger et al., Journal of the International Society of Sports Nutrition, 2017). For GLP-1 users specifically, this is crucially important — a 2024 systematic review and network meta-analysis in Obesity Reviews confirmed that lean muscle mass loss is a real risk for people on GLP-1 receptor agonists, making protein intake one of the most impactful lifestyle variables for protecting your body composition during weight loss.

Meaningful non-scale victories for GLP-1 users include improvements in HbA1c (blood sugar control), blood pressure, resting heart rate, sleep quality, energy levels, clothing fit, and physical endurance. These markers often reflect significant metabolic improvements before meaningful scale changes occur. Clinical trial data from the STEP program (Davies et al., The Lancet Diabetes & Endocrinology, 2021) consistently showed improvements in cardiovascular risk factors and quality-of-life measures alongside weight changes, reinforcing that scale weight is only one piece of the health picture.

Most clinical guidelines support titrating — increasing dose — when appetite suppression has noticeably decreased, when weight loss has plateaued for 4–6 weeks without a clear lifestyle cause, or when current-dose side effects have fully resolved. The STEP 1 trial extension (Wilding et al., Diabetes, Obesity & Metabolism, 2022) demonstrated that appropriate dose escalation continues to drive meaningful weight loss outcomes in people on semaglutide. Always discuss any dose changes with your prescribing provider before adjusting.

Yes — and the science confirms it. Response to GLP-1 medications varies significantly between individuals due to genetic factors, starting metabolic health, gut microbiome, and individual biology. The 2026 Stanford Genome Medicine study (Umapathysivam et al.) is the first to identify a specific genetic mechanism explaining why some people are inherently less responsive to GLP-1 drugs. Slower results are not a reflection of personal failure — they're often a biological reality that can be addressed with provider support, dose optimization, and lifestyle adjustments tailored to your specific body.

What's one mistake you've caught yourself making on your GLP-1 journey — and what helped you course-correct?

Here are a few to get you started — but don't let these limit you:

Or maybe it's something completely different. Hit reply and tell me — I read every single response, and the best answers get featured in next week's issue (with your permission, of course).

Your experience might be exactly what someone else needs to hear right now. 💪

💌 Enjoyed this issue?

📆 See you next week! — The Weekly Dose Team

📢 P.S. Want to read past issues? Click here

⚠️ Some links in this post may be affiliate links. If you make a purchase, we may earn a commission at no extra cost to you. We only recommend products our community actually uses.